Increase of plasma IgE during treatment correlates with better outcome of patients with glioblastoma
查看参考文献31篇
|
文摘
|
Background: Previous studies have shown that glioma patients have lower blood IgE levels than controls. To evaluate its potential as a surrogate biomarker for glioma, we measured plasma IgE levels in glioma patients and healthy controls, and correlated them with clinicopathological factors and the patients' outcome. Methods: We used enzyme-linked immunosorbant assay (ELISA) to determine the plasma IgE levels of 25 normal subjects and 252 glioma patients (85 patients with grade II glioma, 46 patients with grade III glioma, and 121 patients with glioblastoma). We also collected longitudinal plasma samples from glioblastoma patients and compared the plasma IgE levels before operation, one week after operation, in the middle of radiotherapy, after two cycles of chemotherapy, and after recurrence. The correlations between plasma IgE levels and the outcomes of the patients were determined. Results: Plasma IgE levels were significantly lower in glioma patients (P=0.004); patients with low-grade glioma have lower IgE levels than patients with high-grade glioma do (P=0.029). In 24 patients with both preoperative plasma and two-cycle chemotherapy plasma samples, IgE levels increased after successful removal of the tumor (P=0.021), and the increase correlated with the patients' survival (increase >100 ng/ml vs. ≤100 ng/ml, 127.5 weeks vs. 62.3 weeks. P=0.012, log-rank). Plasma IgE level increase of >100 ng/ml has a specificity of 80% and a sensitivity of 78% to predict the patients' long survival (>18 months). Conclusions: Our results suggest that plasma IgE level correlates with clinical and pathological factors in glioma patients. It has the potential to be a biomarker for glioma patients. |
|
来源
|
Chinese Medical Journal
,2011,124(19):3042-3048 【核心库】
|
|
DOI
|
10.3760/cma.j.issn.0366-6999.2011.19.016
|
|
关键词
|
Glioblastoma
;
Immunoglobulin E
;
Plasma
;
Prognosis
|
|
地址
|
1.
Department of Neurosurgery, First Affiliated Hospital, China Medical University, Liaoning, Shenyang, 110001
2.
Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100050
|
|
语种
|
英文 |
|
文献类型
|
研究性论文 |
|
ISSN
|
0366-6999 |
|
学科
|
外科学 |
|
基金
|
国家863计划
;
国家973计划
;
国家自然科学基金
|
|
文献收藏号
|
CSCD:4321538
|
参考文献 共
31
共2页
|
|
1.
Minniti G. Chemotherapy for glioblastoma: Current treatment and future perspectives for cytotoxic and targeted agents.
Anticancer Research,2009,29(12):5171-5184
|
CSCD被引
4
次
|
|
|
|
|
2.
.
Statistical Report On Public Health In China,2010
|
CSCD被引
1
次
|
|
|
|
|
3.
Giannini C. Anaplastic oligodendroglial tumors: Refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402.
Brain Pathology,2008,18(3):360-369
|
CSCD被引
5
次
|
|
|
|
|
4.
Huang L. Correlations between molecular profile and tumor location in Chinese patients with oligodendroglial tumors.
Clinical Neurology and Neurosurgery,2008,110(10):1020-1024
|
CSCD被引
1
次
|
|
|
|
|
5.
Hegi M E. MGMT gene silencing and benefit from temozolomide in glioblastoma.
New England Journal of Medicine,2005,352(10):997-1003
|
CSCD被引
150
次
|
|
|
|
|
6.
Van Den Bent M J. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: A report from EORTC brain tumor group study 26951.
Journal of Clinical Oncology,2009,27(35):5881-5886
|
CSCD被引
8
次
|
|
|
|
|
7.
Greene K L. Prostate Specific Antigen Best Practice Statement: 2009 Update.
Journal of Urology,2009,182(5):2232-2241
|
CSCD被引
11
次
|
|
|
|
|
8.
Goonewardene T I. Management of asymptomatic patients on follow-up for ovarian cancer with rising CA-125 concentrations.
Lancet Oncology,2007,8(9):813-821
|
CSCD被引
2
次
|
|
|
|
|
9.
Johnson P J. The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma.
Clinics in Liver Disease,2001,5(1):145-159
|
CSCD被引
27
次
|
|
|
|
|
10.
Lin Y. Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas.
Neuro-Oncology,2009,11(5):468-476
|
CSCD被引
2
次
|
|
|
|
|
11.
Hormigo A. YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas.
Clinical Cancer Research,2006,12(19):5698-5704
|
CSCD被引
9
次
|
|
|
|
|
12.
Jung C S. Serum GFAP is a diagnostic marker for glioblastoma multiforme.
Brain,2007,130(12):3336-3341
|
CSCD被引
4
次
|
|
|
|
|
13.
Fukuda M E. Cathepsin D is a potential serum marker for poor prognosis in glioma patients.
Cancer Research,2005,65(12):5190-5194
|
CSCD被引
5
次
|
|
|
|
|
14.
Ahlbom A. Epidemiologic evidence on mobile phones and tumor risk: A review.
Epidemiology,2009,20(5):639-652
|
CSCD被引
3
次
|
|
|
|
|
15.
Holick C N. Coffee, tea, caffeine intake, and risk of adult glioma in three prospective cohort studies.
Cancer Epidemiology Biomarkers and Prevention,2010,19(1):39-47
|
CSCD被引
2
次
|
|
|
|
|
16.
Wiemels J L. IgE, allergy, and risk of glioma: Update from the San Francisco Bay Area Adult Glioma Study in the Temozolomide era.
International Journal of Cancer,2009,125(3):680-687
|
CSCD被引
1
次
|
|
|
|
|
17.
Melbye M. Atopy and risk of non-hodgkin lymphoma.
Journal of the National Cancer Institute,2007,99(2):158-166
|
CSCD被引
1
次
|
|
|
|
|
18.
Petridou E T. Breast cancer risk in relation to most prevalent IgE specific antibodies: A case control study in Greece.
Anticancer Research,2007,27(3 B):1709-1713
|
CSCD被引
3
次
|
|
|
|
|
19.
Tsavaris N. Preliminary evaluation of the potential prognostic value of serum levels of immunoglobulins (IgA, IgM, IgG, IgE) in patients with gastric cancer.
International Journal of Biological Markers,1998,13(2):87-91
|
CSCD被引
1
次
|
|
|
|
|
20.
Schoemaker M J. Interaction between 5 genetic variants and allergy in glioma risk.
American Journal of Epidemiology,2010,171(11):1165-1173
|
CSCD被引
2
次
|
|
|
|
|
了解气象卫星更多信息，请访问